Irreversible sensorineural hearing loss due to Imatinib.
OBJECTIVE
We report probably the first case of bilateral irreversible sensorineural hearing loss caused by Imatinib.


METHODS
A review of the world literature, concerning Imatinib toxicity is presented.


RESULTS
We report a case of bilateral irreversible sensorineural hearing loss, in a 19-year-old male patient of chronic myeloid leukemia after 3 months of Imatinib therapy. Audiometric evaluation documented the findings.


CONCLUSIONS
To the best of our knowledge, this is the first case report of Imatinib induced sensorineural hearing loss. This case indicates that treating oncologists should keep in mind that this drug too can produce ototoxicity.
Attili
Venkata Satya Suresh
VS
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560029, India. sureshattili@yahoo.com
Bapsy
P P
PP
Anupama
G
G
Lokanatha
D
D
D000328:Adult; D001549:Benzamides; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases